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Purpose: Although neoadjuvant therapy has been accepted as a treatment option in 
locally-advanced gastric cancer, its prognostic value has been difficult to evaluate. 
Materials and Methods: Seventy-four gastric cancer patients who underwent gas-
trectomy after neoadjuvant treatment were divided into two groups according to the 
pathologic response: favorable (ypT0) and others (ypT1-4). The clinicopathologic 
characteristics, predictive factors for pathologic response, and oncologic outcome 
were evaluated. Results: Eleven patients (14.8%) demonstrated ypT0 and the re-
maining 63 patients (85.2%) were ypT1-4. Chemoradiotherapy (CCRTx) rather than 
chemotherapy (CTx) was the only predictive factor for a favorable pathologic re-
sponse. Chemotherapeutic factors and tumor marker levels did not predict pathologic 
response. The 1-, 2-, and 3-year disease-free survivals were 83.4%, 70%, and 52.2%. 
The 1-, 3-, 5-year overall survivals were 88.5%, 67.5%, and 51.2%, respectively. Al-
though a complete pathologic response (ypT0N0M0) was achieved in 7 patients, 
28.6% of them demonstrated recurrence of the tumor within 6 months after curative 
surgery. Conclusion: CCRTx rather than CTx appears to be more effective for 
achieving good pathologic response. Although favorable pathologic response has 
been achieved after neoadjuvant treatment, the survival benefit remains controversial.
Key Words:   Gastric cancer, neoadjuvant chemotherapy, neoadjuvant chemora-
diotherapy, gastrectomy, pathologic response, prognosis
INTRODUCTION
Although complete surgical removal represents the only curative treatment for gas-
tric cancer, preoperative chemotherapy (CTx) and chemoradiotherapy (CCRTx) 
have been increasingly used over the past decades for advanced gastric cancer 
with the goals of tumor downstaging and increasing the rates of curative surgical 
resection and survival.
The benefits of preoperative CTx and CCRTx in gastric cancer have been widely 
reported in Western trials. For locally-advanced gastric cancer, the R0 resection rate 
was 70% to 80%, and the complete pathologic response rate was 15% to 30%.1-4 
However, in Eastern countries, including Korea and Japan, the primary treatment 
for locally-advanced gastric cancer is surgical resection. Many surgeons prefer the 
aggressive or extended surgical resection to medical treatment and worry that pa-
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For the combination of three regimens, 5-FU, platinum and 
taxol were used. Patients were divided into three groups ac-
cording to the total number of cycles of preoperative CTx: 
1) ≤3 cycles; 2) 4-6 cycles; and 3) >6 cycles. Patients re-
ceived either CTx (n=55) or CCRTx (n=19), and there was 
no crossover between groups. The total preoperative radio-
therapy dose was 4500 cGy.
Surgical treatment included standard or extended gastrec-
tomy with lymph node dissection according to the guide-
lines of the Japanese Gastric Cancer Association.5 
Because the standard extent of lymph node dissection in 
advanced gastric cancer is D2, most patients received D2 
lymph node dissection. However, some patients with non-
curative resection received D1+b lymph node dissection. 
Extended gastrectomy included resection of adjacent or-
gans, such as the spleen, colon, pancreas, small bowel, and 
liver, in addition to the subtotal or total gastrectomy. R0 re-
section indicates a complete resection with no gross evi-
dence of residual tumor. R1 resection refers to tumor in-
volvement of the margins of the resected tissue when viewed 
microscopically, and R2 resection indicates that portions of 
visible tumor were not removed.
Evaluation
Clinicopathologic characteristics, such as sex, age, Ameri-
can Society of Anesthesiologists (ASA) score, tumor loca-
tion, histologic type, number of chemotherapeutic regi-
mens, number of chemotherapeutic cycles, and laboratory 
markers, were examined based on ypT status. Laboratory 
data included carcinoembryonic antigen, cancer antigen 72-
4, cancer antigen, white blood cell count, neutrophil and 
lymphocyte count. The initial pretreatment values and pre-
operative values after CTx or CCRTx were checked. Surgi-
cal outcomes including the extent of resection, extent of 
lymph node dissection, operative time, and postoperative 
complications were also evaluated.
After R0 resection, the incidence of tumor recurrence and 
recurrence pattern were evaluated according to the ypT and 
ypN status. The tumor recurrence patterns were classified as 
lymphatic, peritoneal, hematogenous, and multiple recur-
rences. The evaluation of the pathologic stage was based on 
the 7th edition of the International Union Against Cancer 
Classification.6 The overall survival (OS) rate was calculated 
from the day of surgical resection until the time of death.
Statistical analysis
Statistical analysis was performed using SPSS® version 
tients can miss the chance for cure during the preoperative 
treatment due to disease progression. Therefore, preopera-
tive treatment is not widely performed in Eastern countries, 
and data for oncologic outcomes in patients with neoadju-
vant treatment are lacking. Therefore, postoperative patho-
logic stages are not able to exactly reflect the preoperative 
and initial tumor stage because of tumor regression and re-
lated histopathologic deformation.
In recent years, more patients have been diagnosed with 
locally-advanced gastric cancer who underwent gastrecto-
my after preoperative treatment such as CTx or CCRTx. 
The outcomes were mixed, demonstrating both excellent 
and poor pathologic responses. Therefore, we evaluated the 
data from gastric cancer patients who underwent surgical 
treatment after preoperative CTx or CCRTx to identify fac-





The surgical and pathologic data of 74 patients who under-
went gastrectomy with lymph node dissection after preop-
erative CTx or CCRTx between 2000 and 2010 due to local-
ly advanced gastric cancer were reviewed. These patients 
had advanced gastric cancer with regional lymph node me-
tastasis and there was no distant metastasis in preoperative 
evaluation including endoscopic and radiologic imaging. 
Their preoperative treatment was done with the intent of 
neoadjuvant therapy. 
Patients were divided into two groups according to the 
postoperative pathologic results: favorable response (ypT0) 
or others (ypT1-4). The ypT0 group included patients with 
no evidence of residual cancer in the stomach regardless of 
lymph node status. The ypT1-4 group included all patients 
with residual tumor in the stomach. All patients had histo-
logically-confirmed adenocarcinoma in the stomach preop-
eratively.
Preoperative CTx or CCRTx and surgical treatment
The preoperative CTx regimen consisted of two or three of 
the following drug combinations: 5-fluorouracil based regi-
mens (5-FU, capecitabine, S-1), leucovorin, platinum (cispla-
tin, oxaliplatin), taxol (taxotere, docetaxel), and irinotecan. 
The combination of two regimens included 5-FU with plati-
num, 5-FU with leucovorin, and irinotecan with platinum. 
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9 patients (12.7%) could not undergo R0 resection: perito-
neal seeding (n=8) and positive margins on resection (n=1). 
The mean number of retrieved lymph nodes was 39.0±17.7 
in the ypT0 group and 38.0±17.3 in the ypT1-4 group. 
There were no significant differences in postoperative com-
plications and the duration of hospital stay between the two 
groups.
Survival of patients according to ypT and ypN status
Over the median 25-month follow-up, the 1-, 2-, and 3-year 
disease-free survival rates were 83.4%, 70.0%, and 52.2%, 
respectively. The 1-, 3-, and 5-year overall survival rates 
were 88.5%, 67.5%, and 51.2%, respectively. The survival 
curves were plotted for the ypT and ypN status (Figs. 1 and 
2). The survival curve for ypN status reflected patients’ 
prognoses better than ypT status. The modality of preopera-
tive treatment (CCRTx vs. CTx) and the postoperative che-
motherapy were not associated with patient survival.  
Tumor recurrence after R0 resection
As shown in Table 3, patients were divided according to the 
ypT and ypN status and evaluated for tumor recurrence. 
Among 7 patients with ypT0N0, 2 (28%) patients showed 
tumor recurrence 4.7 months and 6.1 months after radical 
gastrectomy. The 2 patients with tumor recurrence were 
among the 5 patients who did not receive postoperative CTx. 
Neither of the 2 patients who received postoperative CTx 
showed tumor recurrence in patients with ypT0N0. Among 
the 3 patients with ypT0N1, only the one patient who did 
not receive postoperative CTx had a tumor relapse.
None of the patients with ypT1N0 (n=3) showed recur-
rence, and only 1 of 5 patients with ypT2N0 exhibited tu-
mor recurrence. Recurrence rates were 33% to 50% in pa-
tients with ypT3 according to the ypN status. Recurrence 
rates ranged from 25% to 100% in those patients with 
ypT4. Tumor recurrence following gastrectomy generally 
occurred within a few months in most patients. 
DISCUSSION
Gastrectomy with D2 lymph node dissection and extended 
surgery for resection of involved organs is the current stan-
dard of care for advanced gastric cancer.5,7,8 In recent years, 
a multidisciplinary treatment approach, including perioper-
ative CTx, radiotherapy, and targeted therapy, has emerged 
for advanced gastric cancer, resulting in increased curability 
15.0 for Windows® (SPSS, Chicago, IL, USA). Categorical 
variables were analyzed using the chi-square or Fisher’s ex-
act test, and continuous data were analyzed using the Mann-
Whitney U test. Data are presented as mean±standard devia-
tion. OS curves were calculated in months based on the 
length of time between primary surgical treatment and final 
follow-up or death using the Kaplan-Meier method. The 
log-rank test was used to assess the statistical differences be-




Preoperative clinicopathologic and therapeutic 
characteristics
Out of the 74 patients, 11 patients (14.8%) showed favor-
able response (ypT0) and had no residual cancer in the re-
sected stomach. The residual tumor status, clinical features, 
type of preoperative therapy, and tumor characteristics are 
displayed in Table 1.
Age, sex, preoperative ASA score, tumor location, and 
histologic type were not predictive factors for a favorable 
pathologic response after CTx or CCRTx. In addition, the 
presence of adjacent organ invasion at the time of initial di-
agnosis noted on abdomen-pelvis computed tomography 
and/or endoscopic ultrasound was not predictive of patho-
logic response. The ypT0 rate was higher in patients with 
CCRTx than in CTx only (p=0.027). The incidence of a fa-
vorable response (i.e., ypT0) was 31.6% in the CCRTx group 
and only 9.1% in the CTx group. The number of preopera-
tive chemotherapeutic regimens and total number of che-
motherapy cycles were not associated with the pathologic 
response. The levels of the initial and preoperative tumor 
markers did not predict the pathologic response.
Surgical outcomes according to the pathologic tumor 
status
There were no significant differences in surgical outcomes, 
including the extent of resection, lymph node dissection, 
curability, operative time, number of retrieved lymph nodes, 
and postoperative hospital stay, between the ypT0 and 
ypT1-4 groups (Table 2). The ypT1-4 group was associated 
with a more advanced ypN status than the ypT0 group.
Four of the 11 patients in the ypT0 group underwent total 
gastrectomy. Seven patients in the ypT0 group exhibited 
ypN0, which indicated an approximately 9% (7 out of 74) 
rate of complete pathologic remission. In the ypT1-4 group, 
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able response to preoperative treatment. We found that histo-
logical type, preoperative chemotherapeutic regimens, and 
tumor markers were not associated with a favorable re-
sponse. The only factor related to the favorable response was 
the type of preoperative treatment; either CTx or CCRTx. Al-
though our curative resection rate was 87.8% (65 out of 74 
patients), which is similar to other studies,2-4 our rate of com-
plete pathologic response was only 9.4% (7 out of 74 pa-
and improved survival. Recent studies have suggested that 
neoadjuvant CTx in patients with unresectable, locally-ad-
vanced or metastatic gastric cancer can offer a chance for 
curative resection and improved survival.9,10
In the present study, we focused on identifying clinical fac-
tors predictive of an excellent response to preoperative CTx 
or CCRTx. As shown in Table 1, several clinicopathological 
factors were analyzed to find the predictive factor for favor-
Table 1. Comparison of Preoperative Clinical, Therapeutic, and Tumor Features
ypT0 (n=11) ypT1-4 (n=63) p value*
Sex 0.740
    Male      7 (14.0) 43 (86.0)
    Female      4 (16.7) 20 (83.3)
Age (yrs)         61.2±9.4 55.3±11.7  0.105†
ASA score 0.367
    1      8 (13.8) 50 (86.2)
    2      2 (14.3) 12 (85.7)
    3      1 (50.0)   1 (50.5)
Tumor location (in stomach) 0.649
    Upper      3 (13.0) 20 (87.0)
    Middle    1 (9.1) 10 (90.9)
    Lower      7 (19.4) 29 (80.6)
    Entire 0 (0)  4 (100)
Histology 0.740
    Differentiated      3 (12.0) 22 (88.0)
    Undifferentiated      8 (16.3) 41 (65.1)
Initial adjacent organ invasion† 1.000
    Absent      6 (14.0) 37 (86.0)
    Present      5 (16.1) 26 (83.9)
Preop CTx vs. CCRTx 0.027
    CTx only    5 (9.1) 50 (90.9)
    CCRTx      6 (31.6) 13 (68.4)
No. of preop CTx regimens 0.331
    2 regimens      8 (19.0) 34 (81.0)
    3 regimens    3 (9.4) 29 (90.6)
Total cycles of preop CTx 0.543
    ≤3      6 (54.5) 31 (49.2)
    4-6    2 (8.7) 21 (91.3)
    >6      3 (21.4) 11 (78.6)
Laboratory data
    Initial CEA (ng/mL)     4.5±5.4   40.6±153.9  0.972‡
    Preop CEA (ng/mL)     1.7±0.9   5.8±19.1  0.212‡
    Initial CA72-4 (U/mL)     4.2±3.6 23.3±57.8  0.688‡
    Preop CA72-4 (U/mL)     3.1±2.7 13.9±36.1  0.212‡
    Initial CA19-9 (U/mL)       9.7±14.5   366.8±1290.6  0.166‡
    Preop CA19-9 (U/mL)       78.9±223.2 112.4±519.6  0.542‡
ASA, American Society of Anethesiologists; CA, cancer antigen; CEA, carcinoembryonic antigen; CT, computed tomography; CTx, chemotherapy; CCRTx, 
chemoradiotherapy; EUS, endoscopic ultrasound.
*Chi-square. 
†Initial adjacent organ invasion was evaluated by abdomen-pelvis CT scan and/or EUS before CTx or CCRTx. 
‡Mann-Whitney U test, mean±standard deviation. Significant values are indicated in bold face. Values in parentheses are percentages.
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sponse rate was lower than the reported 15% to 30 % in pre-
vious prospective studies.1,2,4 Overall, we were able to identi-
fy ypT0 patients as those patients likely to have a favorable 
tients). Because this study was retrospective in nature, the 
chemotherapeutic protocols varied among the patients, 
which might explain why our 9.4% complete pathologic re-
Table 2. Surgical Outcomes and Pathologic Results According to ypT Status
ypT0 (n=11) ypT1-4 (n=63) p value*
Resection extent 0.161
    Subtotal      7 (63.6) 24 (38.1)
    Total      4 (36.4) 27 (42.9)
    Extended 0 (0) 12 (19.0)
Extent of LND 0.387
    <D2    1 (9.1) 2 (3.2)
    ≥D2    10 (90.9) 61 (96.8)
Curability 0.409
    R0   11 (100) 54 (85.7)
    R1 R2 0 (0)   9 (12.7)
Operation time (min) 184.5±105.3 192.0±45.1  0.821†
Blood loss (g) 206.2±205.1 194.1±279.6  0.892†
Transfusion 0.277
    No    10 (90.9) 62 (98.4)
    Yes    1 (9.1) 1 (1.6)
No. of retrieved LNs 39.0±17.7 38.0±17.3  0.781†
ypN status 0.027
    ypN0      7 (63.6) 17 (27.0)
    ypN1       3 (27.3) 10 (15.9)
    ypN2    1 (9.1) 16 (25.4)
    ypN3 0 (0) 20 (31.7)
ypM status 0.596
    ypM0   11 (100) 55 (87.3)
    ypM1 0 (0)   8 (12.7)
Hospital stay (no complication) 8.5±2.1 9.1±2.6  0.562†
Postoperative complications 0.718
    No      9 (81.8) 46 (73.0)
    Yes      2 (18.2) 17 (27.0)
LND, lymph node dissection; LNs, lymph nodes.
*Chi-square.
†Student’s t-test, mean±standard deviation. Values in parentheses are percentage.
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tions of preoperative CCRTx or CTx were not well estab-
lished in our institute, CTx or CCRTx was done arbitrarily 
according to the surgeons’ or oncologists’ decision in local-
ly far advanced gastric cancer. Therefore, our data cannot 
offer conclusive evidence. It can only provide some clues 
for achieving better survival in advanced gastric cancer, 
which should be solved by more prospective studies.
The prognosis of patients with a favorable response was 
poorer than anticipated in our results, because two of our 
seven patients (28.6%) with complete pathologic response 
experienced tumor recurrence within a short time. These 
two patients did not receive adjuvant CTx; however, two pa-
tients with ypT0N0 who received adjuvant treatment did 
not experience tumor recurrence (Table 3). When the tumor 
was in the advanced stage, despite neoadjuvant treatment, 
the prognosis was very poor. Tumor recurrence developed 
rapidly, with the majority recurring within 12 months even 
after R0 resection. Therefore, postoperative adjuvant treat-
ment may be necessary regardless of the surgical pathology 
stage. Because of the small number of patients, the survival 
response to preoperative treatment regardless of ypN status.
Neoadjuvant CCRTx was more effective than neoadju-
vant CTx for tumor regression in gastric cancer. The favor-
able response rate (ypT0) was 31.6% after CCRTx and 
only 9.1% after CTx. In addition, the incidence of ypN0 was 
47.4% (9 patients) after CCRTx and 27.3% (15 patients) af-
ter CTx. The impact of preoperative CTx or CCRTx in 
esophagogastric junction (EGJ) cancer was observed in 
several Western studies.11,12 Additionally, one phase III study 
comparing CTx and CCRTx showed a higher complete 
pathologic response rate in the preoperative CCRTx group 
than in the preoperative CTx group.13 Although these West-
ern studies focused on esophageal and EGJ cancer, the su-
periority of adding radiation therapy to preoperative CTx 
may be applied to gastric cancer, too.
However, in this retrospective study, the initial tumor sta-
tus and the treatment efficacy for CCRTx and CTx in histo-
logic tumor regression of gastric cancer could not be direct-
ly compared. Moreover, because the preoperative treatment 
of the neoadjuvant intent was not routine and the indica-
Table 3. Tumor Recurrence and Pathologic Status in Patients with R0 Resection






Time to recurrence 
(months)
T0 N0 7 Yes 2 0
No 5 2   28.6 1 H, 1 L 4.7, 6.1
N1 3 Yes 2 0
No 1 1   33.3 1 M (H) 6.0
N2 1 Yes 1 0     0
T1 N0 3 No 3 0     0
N3 1 Yes 1 1 100 1 L 3.4
T2 N0 5 Yes 4 1   20.0 1 P 2.4
No 1 0
N1 3 Yes 1   33.3 1 M (P) 7.4
T3 N0 6 Yes 4 1   33.3 2 P 13.1
No 2 1 9.8
N1 4 Yes 4 2   50.0 2 H 1.2
21.2
N2 8 Yes 7 3   50.0 3 P 1.1, 6.9, 18.2
No 1 1 1 L 1.0
N3 2 Yes 2 1   50.0 1 L 12.9
  T4a N0 2 No 2 1   50.0 1 H 1.6
N1 2 Yes 2 2 100 1 P 1.7
1 H 25.1
N2 8 Yes 8 2   25.0 1 H 5.4
1 M (L) 8.8
N3 9 Yes 8 6   77.8 4 P 3.0, 3.7, 7.0, 19.1 
2 L 8.5, 10.3
 No 1 1 1 P 16.9
 T4b N3 1 Yes 1 1 100 1 L 2.3
H, hematogenous; L, lymphatic; P, peritoneal; M, multiple combined metastasis.
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analysis at each stage had some limitations. The rationale 
for adjuvant CTx in patients with complete pathologic re-
mission is not conclusive; however, this study may offer 
clues toward improvement in the treatment of advanced gas-
tric cancer with neoadjuvant therapy. 
This retrospective study design resulted in several limita-
tions, including the inability to strictly evaluate the initial tu-
mor stage before neoadjuvant treatment and the lack of con-
sistency with respect to the diagnostic modalities and 
neoadjuvant treatment protocols. It was difficult to determine 
whether patient survival was better represented by the initial 
tumor stage or the final pathologic tumor stage. Additionally, 
the degree of histologic tumor regression by neoadjuvant 
treatment was not evaluated in all patients. These drawbacks 
would be overcome with a prospective randomized study.
In summary, concurrent CCRTx rather than CTx alone 
appeared to be more effective with respect the pathologic 
response in locally-advanced gastric cancer and postopera-
tive nodal status appeared to reflect patients’ prognoses bet-
ter than ypT status. Although favorable pathologic response 
by neoadjuvant treatment was achieved, survival was not as 
good even after radical surgery. Overall, these results sug-
gest the survival benefit of neoadjuvant treatment regard-
less of the fact that resectability remains controversial.
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